Enrollment concluded for study of cord blood stem cell product

stem-cells.jpg

Gamida Cell has that the company's joint venture with Teva Pharmaceutical Industries has completed enrollment of the last of 100 patients for their international, multi-center, pivotal registration, Phase III clinical trial of StemEx, the cell therapy product being developed as an alternative therapeutic treatment for people with leukemia or lymphoma who need a stem cell transplant but can not find a matched donor.

According to the press release, StemEx is "a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV administration along with the remaining, non-manipulated cells from the same unit."

The hope is that the companies can bring StemEx to market in 2013.

Source: BusinessWeek

LymphomaInfo Social